Presidential Science Aide Got Funding from Hwang
By Chosun Ilbo,
Chosun Ilbo
| 01. 17. 2006
The presidential advisor for science and technology Park Ky-young admitted Tuesday to a conflict of interest arising from W250 million (US$250,000) in research grants she received from the disgraced cloning scientist Hwang Woo-suk. Hwangîs motives have come under suspicion because although Park received the money when she was still a botanist at Sunchon National University in South Jeolla Province and before taking the Cheong Wa Dae post in 2004, she already had the presidentîs ear at the time. She insists the funding was spent in a transparent manner.
"I accepted W150 million from Hwang, who was in charge of producing a BSE-resistant cow in December 2001, when I was working as a botany professor at Sunchon National University, to carry out research projectsñ on social implications and research ethics, she said.
She said Hwang gave her another W100 million in June 2003, asking her to study the ethical and industrial impact of bio-organs, as part of a project on producing bio-organs by using transgenic cloning technology and developing transplant technology. Park was appointed presidential aide the following year.
The official...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...